Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT07321951Phase 2Active, not recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SHR-1819 in atopic dermatitis (AD) (3 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Eczema Area and Severity Index 75% reduction at 24 weeks. Started Jan 2026; status: active, not recruiting.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07321951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321951.